INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10596589		
	Filing Date		2006-06-16		
	First Named Inventor Maru		faruyama, et al.		
	Art Unit		1762		
	Examiner Name Unkn		nknown		
	Attorney Docket Number		118076-002	-	

Under the Paperwork Reduction Act of 1995, no persons a

					U.S.	PATENTS					
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Dat	le	Name of Patentee or Applicant of cited Document		Rel	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	dd additional U.S. Pate	ent citatio	n informati	ion pl	lease click the	Add button.				
			U.S.P	ATENT A	PPLK	CATION PUB	LICATIONS				
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	on	Name of Patentee or Applicant of cited Document		Rel	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	dd additional U.S. Pub	lished Ap	oplication c	itatio	n information	please click the A	dd but	ton.		
				FOREIGN	PAT	TENT DOCUM	IENTS				
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		and ode4	Publication Date	Name of Paten Applicant of cite Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TX	
	1										
If you wis	h to a	dd additional Foreign F	Patent Do	cument cit	ation	information p	lease click the A	id butte	on	_	
			NON	N-PATENT	LITE	RATURE DO	CUMENTS		4.4.4		
Examiner Initials*	Cite No	include name of the (book, magazine, jou publisher, city and/or	mal, seri	al, sympos	ium,	catalog, etc),			priate), title of the item issue number(s),	Тs	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10596589		
	Filing Date		2006-06-16		
	First Named Inventor Maru		aruyama, et al.		
	Art Unit		1762		
	Examiner Name	Unkn	known		
	Attorney Docket Number		118076-002		

	LAHANN; KLEE; HOCKER, "Chemical vapour deposition polymerization of substituted [2.2]paracyclophanes"; Macromolecular Rapid Communications 19, No. 9, 1998; pp. 441-444; WILEY-VCH Verlag GmbH, D-69451;

If you wish to add additional non-patent literature document citation information please click the Add button

# EXAMINER SIGNATURE

Date Considered

Examiner Signature

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Grot Codes of USPTO Petert Documents at time USETO CODY or MREP 80104. \* Enter of this that issued the document, by the tro-better code (MPC) Standard ST3, 1 \*\*Enter price parted counters, the includation on the year of the region of the Emporer manufactorist the relationshape of the parted from the product the relation tunned of the parted from the product the relation code for death remained on the parted from the product the product that the product the parted from the product the product that the product the product that the product t

#### 

## CERTIFICATION STATEMENT

Diagea eaa 37 CE	D 1 97 and 1 98 to	make the announciate	eplorting/e).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1976/11.

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making resonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.

  Fee set forth in 37 CFR 1.17 (o) has been submitted berewith.
- ☑ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas C. Basso/	Date (YYYY-MM-DD)	2007-01-10
Name/Print	Thomas C. Basso	Registration Number	46.541

This collection of information is required by 37 CPR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to life jand by the USPT to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CPR 1.14. This collection is estimated to take 1 hour to complete, including pathering, preparing and submitting the completed application from the USPTO. Them will vary depending upon the individual case. Any comments on the amount of time you require to complete this from and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petitot and Trademark Office, U.S. operationed for Comment of Comment of USPTO. The USPTO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, V.2 2311.4450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked from related to a petient application or patiert. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited to is columitary, and (3) the privincial pursuance for which the information is used by the U.S. Patient and Trademark Chine is to process and/or examine your submission related to a patient agriculture or patient. If you do not furnish the requested process and/or examine your submission related to a patient agriculture or patient. If you do not furnish the requested many control or patients of the p

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records mod obscosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement necotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. SSZafm.
  - A record related to an international Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Sarvices, or hisher designe, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2908. Such disclosure shall be made in accordation with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations of south individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 152(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitation of 37 CFR 1.14, as a routine use, to the public if the rocord was filled in a application which became abandoned or in which the proceedings were terminated and which application is referenced by either a qualished anoticiation, an application open to qualish characteristics.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.